EGR1 and breast cancer: By suppressing the expression of SUV420H2, which leads to the loss of H4K20me3, miR-29a attenuates the repression of CTGF and EGR1 by H4K20 trimethylation and promotes the EMT progress and metastasis of breast cancer cells.